Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 14/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048759 | 0.89 | ALDH1A1 (0.56) | ALDH1A1TDP1TP53HCRTR2ALPL | |
| SCHEMBL1055274 | 0.88 | NPC1 (0.50) | ALDH1A1TDP1TP53HCRTR2ALPL | |
| SCHEMBL1052310 | 0.87 | ALDH1A1 (0.54) | ALDH1A1TDP1TP53HCRTR2ALPL | |
| SCHEMBL1053127 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TDP1TP53HCRTR2ALPL | |
| SCHEMBL1054861 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TDP1TP53HCRTR2ALPL | |
| SCHEMBL1052728 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TDP1TP53HCRTR2ALPL | |
| SCHEMBL1054852 | 0.86 | TSHR (0.53) | ALDH1A1TDP1TP53HCRTR2ALPL | |
| SCHEMBL1051045 | 0.84 | POLB (0.58) | ALDH1A1TDP1TP53POLB | |
| SCHEMBL1053730 | 0.84 | ALDH1A1 (0.56) | ALDH1A1TDP1TP53ALPLPOLB | |
| SCHEMBL1055548 | 0.84 | SLC22A12 (0.56) | ALDH1A1HCRTR2ALPLHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868026-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868026-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868026-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1937639-B1 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| WO-2007034312-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167497-A1 | Therapeutic Compounds | SLC10A1, PCSK9, CFTR | ALDH1A1 310/4885TDP1 3949/4885TP53 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.